Brazil is taking an important step toward the future of healthcare with the Genomas Brasil Program, an initiative of the Ministry of Health launched in 2020. Its goal is to use knowledge about the DNA of the Brazilian population to make healthcare more precise, effective, and personalized within the Unified Health System (SUS), which provides free care to more than 200 million people.
In practice, this means better understanding how each person’s genetic characteristics influence the development of diseases and responses to treatments. With this information, physicians will be able, in the future, to provide faster diagnoses and more suitable therapies for each patient.
To achieve this, the program has set ambitious goals. These include creating a reference “genetic map” of the Brazilian population, building a large national database with genetic and health information, and strengthening science and technology in the country. So far, projects have been supported that are expected to sequence around 118,000 genomes – approximately 60,000 already completed – generating an unprecedented knowledge base on Brazil’s genetic diversity. Overall, the initiative has already invested billions of reais in more than 260 research projects.
These data help improve the understanding of diseases such as cancer, rare conditions, cardiovascular disorders, and infectious diseases, while also supporting the development of new diagnostic tests and treatments. They also contribute to preventive actions, enabling the identification of risks even before symptoms appear.
One of the key initiatives within this effort is the GenomaSUS Project, launched in 2024. In its first phase, the project aimed to sequence 21,000 Brazilians from all regions of the country, ensuring that the population’s diversity is represented. This is essential so that advances in medicine benefit everyone, rather than only specific groups.
With access to a broad and representative dataset, scientists can more accurately identify genetic factors associated with diseases. When combined with clinical and population data, this opens the door to faster diagnoses, personalized treatments, and more efficient use of healthcare resources.
Another important benefit is the reduction of regional inequalities. By investing in infrastructure and capacity building across different parts of the country, the program expands access to innovation and strengthens research centers beyond major urban hubs, making science more inclusive and results more representative of the Brazilian population.
By bringing together science, technology, and institutional collaboration, Genomas Brasil positions the country prominently on the international genomics stage. More importantly, it lays the foundation for a more modern, efficient, and equitable public healthcare system, delivering tangible benefits to millions of Brazilians.
